- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04332549
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
28. mai 2020 oppdatert av: Sun Pharma Advanced Research Company Limited
A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study of Paclitaxel Injection Concentrate for Suspension (PICS) in Subjects With Locally Recurrent or Metastatic Breast Cancer.
A randomized, multi center, open label, two-period, single dose, crossover study to evaluate the bioavailability and safety of Paclitaxel Injection Concentrate for Suspension in Locally Recurrent or Metastatic Breast Cancer subjects.
Studieoversikt
Status
Tilbaketrukket
Intervensjon / Behandling
Studietype
Intervensjonell
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, India, 530017
- SPARC Site 12
-
-
Gujarat
-
Ahmadabad, Gujarat, India, 380016
- SPARC Site 21
-
Sūrat, Gujarat, India, 395002
- SPARC Site 22
-
-
Karnataka
-
Bangalore, Karnataka, India, 560027
- SPARC Site 4
-
Bangalore, Karnataka, India, 560054
- SPARC Site 10
-
Bangalore, Karnataka, India, 560090
- SPARC Site 18
-
Bangalore, Karnataka, India, 560092
- SPARC Site 13
-
-
Maharashtra
-
Aurangabad, Maharashtra, India, 431001
- SPARC Site 9
-
Kolhāpur, Maharashtra, India, 416234
- SPARC Site 8
-
Nagpur, Maharashtra, India, 440003
- SPARC Site 2
-
Nagpur, Maharashtra, India, 440010
- SPARC Site 1
-
Nagpur, Maharashtra, India, 440024
- SPARC Site 17
-
Nashik, Maharashtra, India, 422002
- SPARC Site 3
-
Nashik, Maharashtra, India, 422005
- SPARC Site 19
-
Pune, Maharashtra, India, 411013
- SPARC Site 15
-
Pune, Maharashtra, India, 411044
- SPARC Site 16
-
Pune, Maharashtra, India, 412105
- SPARC Site 5
-
Sāngli, Maharashtra, India, 416410
- SPARC Site 11
-
-
Orissa
-
Khorda, Orissa, India, 751007
- SPARC Site 20
-
-
Tamil Nadu
-
Madurai, Tamil Nadu, India, 625107
- SPARC Site 14
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226003
- SPARC Site 7
-
-
Vadodara
-
Gujrat, Vadodara, India, 391760
- SPARC Site 6
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- The subject has given written, informed consent (or legally acceptable representative /impartial witness when applicable) and is available for the duration of study
- Histologically or cytologically confirmed diagnosis of breast cancer with adequate documentation of prior therapy with an anthracycline unless clinically contraindicated
- Locally recurrent or MBC for which taxane-based therapy is an appropriate treatment option
- Male or female aged greater than equal to 18 years
- ECOG performance status less than equal to 1
- Estimated life expectancy of at least 12 weeks
- Adequate organ and immune system function as indicated by the following laboratory values, obtained less than equal to 2 weeks prior to dosing for Period 1 and Period 2:
- Any chemotherapy, targeted therapy, major surgery, or irradiation must have been completed at least 4 weeks before enrollment (6 weeks for mitomycin C or nitrosurea); immune therapy or hormonal therapy (except palliative bisphosphonate therapy for bone pain) must be completed 2 weeks before enrollment and subjects must have recovered from all toxicities incurred as a result of previous therapy except alopecia; use of targeted therapy or antibody therapy should have been completed for at least 5 half-lives of the respective therapy before enrollment. Use of narcotic analgesics such as dihydrocodeine and medicinal herbs such as St. John's Wort, which may act as inhibitors/inducers of CYP2C8 and CYP3A4, must have been discontinued at least 2 weeks and 4 weeks respectively before enrollment
Subjects of child bearing potential must practice an acceptable method of birth control as judged by the investigator
- Medically acceptable methods of birth control include the use of either a contraceptive implant or a contraceptive injection (e.g., Depo-Provera™) or an intrauterine device, same sex partner or vasectomized partner or an oral contraceptive taken continually within the past three months and which the subject agrees to continue using during the study
- To adopt another birth control method, or a double-barrier method which consists of a combination of any two of the following:
diaphragm, cervical cap, condom, or a spermicide at least 2 months prior to study entry and must continue to use contraception for the duration of the study
- Female subjects who are postmenopausal for at least 1 year as per investigator's discretion, or who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
- Male subjects enrolled in the trial cannot father a child and are advised to prevent passage of semen to their sexual partner during intercourse using acceptable methods as judged by the investigator for the duration of the study
- Females subjects of child-bearing potential must have a negative urine pregnancy test
- Female subjects must be non-lactating and non-breastfeeding
- Subject must be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
Exclusion Criteria:
- Known hypersensitivity to the study drug or their excipients (cholesteryl sulfate, caprylic acid, polyvinylpyrrolidone, ethanol, polyethylene glycol)
- Inability to undergo venipuncture and/or tolerate venous access
- Presence of clinically symptomatic active CNS metastases, including leptomeningial involvement, requiring steroid or radiation therapy
- Pre-existing clinically significant peripheral neuropathy (Grade 2 or higher according to CTCAE, Version 5.0)
- Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study or confound the study
- Presence of pleural/ascitic fluid which cannot be definitively treated prior to dosing and during the PK blood draws in each period (Period 1 and Period 2) and if there is re-accumulation of fluid (greater than 5%) greater than 2 weeks after definitive management
- Positive laboratory exclusion test (HIV, HBsAg, or HCV)
- Treatment with investigational agents or participation in a clinical trial within 30 days of study entry
- Failure of prior taxane therapy for metastatic disease or for adjuvant therapy within previous 6 months of screening visit
- Subjects taking concurrent medications that may act as inhibitors/inducers of CYP2C8 and CYP3A4 within 2 weeks of screening and during Periods 1 and 2
- Evidence or history of bleeding diathesis or coagulopathy within 6 months prior to screening visit
- Uncontrolled cardiac disease, including: congestive heart failure (CHF) > Class II per New York Heart Association (NYHA), history of hypertensive crisis
- Active clinical infection which in the treating investigator's opinion renders the subject ineligible or can confound the study
- Serious non-healing wound, ulcer or bone fracture
- Unresolved toxicity higher than CTCAE Version 5.0 Grade 1 (excluding alopecia, anemia) attributed to any prior therapy/procedure
- History of gastrointestinal perforation within 6 months prior to screening visit.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Reconstitution Method 1
|
dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
|
Aktiv komparator: Reconstitution Method 2
|
dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maximum observed plasma concentration Plasma
Tidsramme: 8 weeks
|
8 weeks
|
|
area under the plasma concentration versus time curve, from time 0 to the last measurable concentration
Tidsramme: 8 weeks
|
8 weeks
|
|
area under the plasma concentration versus time curve from time 0 to infinity
Tidsramme: 8 weeks
|
8 weeks
|
|
Incidence of Treatment-Emergent Adverse Events
Tidsramme: 8 weeks
|
shall be coded per CTCAE, Version 5.0
|
8 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
27. april 2020
Primær fullføring (Forventet)
28. januar 2021
Studiet fullført (Forventet)
28. januar 2021
Datoer for studieregistrering
Først innsendt
26. mars 2020
Først innsendt som oppfylte QC-kriteriene
1. april 2020
Først lagt ut (Faktiske)
2. april 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
1. juni 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
28. mai 2020
Sist bekreftet
1. mai 2020
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SDO-006-20-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Nei
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Metastatisk brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
I-Mab Biopharma Co. Ltd.Ikke lenger tilgjengeligSolid Tumor Metastatic Cancer Advanced Cancer
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
AmgenAktiv, ikke rekrutterendeKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, Forente stater, Canada, Belgia, Spania, Korea, Republikken, Nederland, Storbritannia, Australia, Danmark, Ungarn, Sverige, Taiwan, Hellas, Den russiske føderasjonen, Sveits, Frankrike, Italia, Japan, Polen, Brasil, Tyskland, ...
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på PICS (Reconstitution Method 1 or 2)
-
Northwestern UniversityFullført